- Home
- ESPR vs EVGO Comparison
ESPR vs EVGO Comparison
Compare ESPR & EVGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- EVGO
- Stock Information
- Founded
- ESPR 2008
- EVGO 2010
- Country
- ESPR United States
- EVGO United States
- Employees
- ESPR N/A
- EVGO N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- EVGO Other Specialty Stores
- Sector
- ESPR Health Care
- EVGO Consumer Discretionary
- Exchange
- ESPR Nasdaq
- EVGO Nasdaq
- Market Cap
- ESPR 305.0M
- EVGO 376.5M
- IPO Year
- ESPR 2013
- EVGO N/A
- Fundamental
- Price
- ESPR $0.89
- EVGO $3.83
- Analyst Decision
- ESPR Buy
- EVGO Strong Buy
- Analyst Count
- ESPR 7
- EVGO 10
- Target Price
- ESPR $5.93
- EVGO $5.78
- AVG Volume (30 Days)
- ESPR 5.7M
- EVGO 3.9M
- Earning Date
- ESPR 05-06-2025
- EVGO 05-06-2025
- Dividend Yield
- ESPR N/A
- EVGO N/A
- EPS Growth
- ESPR N/A
- EVGO N/A
- EPS
- ESPR N/A
- EVGO N/A
- Revenue
- ESPR $259,574,000.00
- EVGO $276,954,000.00
- Revenue This Year
- ESPR $5.70
- EVGO $39.82
- Revenue Next Year
- ESPR N/A
- EVGO $32.12
- P/E Ratio
- ESPR N/A
- EVGO N/A
- Revenue Growth
- ESPR 12.99
- EVGO 45.15
- 52 Week Low
- ESPR $0.82
- EVGO $1.78
- 52 Week High
- ESPR $3.94
- EVGO $9.07
- Technical
- Relative Strength Index (RSI)
- ESPR 36.95
- EVGO 79.08
- Support Level
- ESPR $0.93
- EVGO $2.66
- Resistance Level
- ESPR $1.11
- EVGO $4.17
- Average True Range (ATR)
- ESPR 0.10
- EVGO 0.23
- MACD
- ESPR 0.02
- EVGO 0.13
- Stochastic Oscillator
- ESPR 25.10
- EVGO 81.13
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About EVGO EVgo Inc.
EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.